Where Are We Now?
We’re evaluating the innovations of 89 early-stage companies with the potential to help impact pediatric, adolescent, and young adult (PAYA) cancers.
Nearly 95,000 New U.S. Diagnoses Annually
Unevenly distributed. Biologically distinct.
Pediatric
Ages 0–14
9,680
cases per year
Common Diagnoses
- Leukemia28%
- Brain & CNS26%
- Lymphoma10–12%
Adolescent
Ages 15–19
5,660
cases per year
Common Diagnoses
- Lymphoma22%
- Brain & CNS22%
- Leukemia13%
Young Adult
Ages 20–39
79,000
cases per year
Common Diagnoses
- Breast15–18%
- Thyroid10–15%
- Melanoma8–10%
Sources: SEER, American Cancer Society. Young adults are the largest PAYA group by an order of magnitude — and historically the most underserved.
CANCER FUND's PAYA Innovation Pipeline
Pediatric, Adolescent, and Young Adult Investment Prospects by Innovation Type
89
Companies
under review
$755M
Aggregate
capital need
By Innovation Focus
Bar widths shown relative to Therapies (largest category = 100%). Under review does not constitute an offer, solicitation, or recommendation.
HOW WOULD YOU LIKE TO PARTICIPATE?
I want to GIVE to support cancer innovation
Donate by credit or debit card or donor-advised fund (DAF) grant; open to everyone
I want to INVEST to support cancer innovation
Verified accredited investors only; see subscription documents for current minimum and terms
I want to JOIN THE COMMUNITY to follow the future of cancer care
Free to join and follow the innovations moving beyond the lab to patients
I represent a FAMILY OFFICE, FOUNDATION, or INSTITUTIONAL investor
Explore investment and partnership opportunities
CANCER FUND is something different.
It’s a community built on a simple insight that many patients, survivors, and the people who care for them and about them already know but nobody had acted on.
GET INVOLVED
Your perspective matters here.
You don’t need a medical degree or an investment background. Patients, survivors, caregivers, scientists, physicians, and investors all have a seat at the table.
We don’t sit in a boardroom and pick the innovations we support. Our Screening Committee helps review what we’re considering. Initial reviews only take 2-3 minutes. But, as we progress through our evaluation process and our review teams get smaller, our evaluations get progressively more detailed, and take longer.
If you’re interested in being part of it, learn more here.